Stroke, A-Fib Recurrence Low at One Year After AF Ablation

Share this content:
Stroke, A-Fib Recurrence Low at One Year After AF Ablation
Stroke, A-Fib Recurrence Low at One Year After AF Ablation

WEDNESDAY, Dec. 14, 2016 (HealthDay News) -- Stroke and atrial fibrillation (AF) recurrence are low one year after AF ablation, according to a study published online Dec. 9 in the Journal of Cardiovascular Electrophysiology.

Simon Kochhäuser, M.D., from Southlake Regional Health Centre in Newmarket, Canada, and colleagues examined the frequency of stroke and AF recurrence in patients on and off therapeutic oral anticoagulation (OAC) one year after AF ablation. A total of 398 patients were identified from an AF database and were screened for AF recurrence, changes in OAC or antiarrhythmic medication, and the occurrence of stroke or transient ischemic attack.

The researchers found that OAC was discontinued in 69.3 percent of patients. During a median follow-up of 529 days, the researchers found that 1 percent of patients suffered from stroke and 13.8 percent experienced AF recurrence. The chance of AF recurrence was increased in association with persistent AF (49.1 versus 26.8 percent; P = 0.001). There was no difference in CHADS2, CHADS2-VASc-Score, or AF recurrence in patients with versus without stroke. Patients who experienced stroke had a trend toward a higher percentage of coronary artery disease (50 versus 10 percent; P = 0.057).

"The overall risk of stroke and AF recurrence is low in patients with a recurrence free interval of at least 12 months after AF ablation," the authors write. "Of note, recurrence of AF was not associated with a higher risk of stroke in our study population."

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Trials Highlight Benefits, Risks of Testosterone Treatment

Trials Highlight Benefits, Risks of Testosterone Treatment

While trials show it boosts bone density and lowers anemia risk, heart risks also seen

Exercise Most Important Lifestyle Change for Breast CA Survivors

Exercise Most Important Lifestyle Change for Breast CA ...

Those who exercised were about 40 percent less likely to die from disease, review suggests

CMS Rule Set to Stabilize Small Health Insurance Markets

CMS Rule Set to Stabilize Small Health Insurance ...

Rule includes special enrollment period pre-enrollment verification, flexibility in level of cover

is free, fast, and customized just for you!

Already a member?

Sign In Now »